Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Dimerix Limited ( (AU:DXB) ) is now available.
Dimerix has confirmed that BioMarin Pharmaceutical will acquire its US commercial licensing partner, Amicus Therapeutics, in an all-cash deal valuing Amicus at about US$4.8 billion, with the transaction to include the transfer of Amicus’s Dimerix commercial licensing contract and all associated rights and obligations. The US licensing agreement for DMX-200 remains intact, leaving Dimerix eligible for up to US$590 million in milestone and upfront payments plus tiered royalties, while its existing ex-US licensing deals with Advanz Pharma, Taiba and Fuso are unaffected and collectively offer up to around A$1.4 billion in potential payments, bolstering the company’s funding base and strategic position as it advances the Phase 3 ACTION3 trial in FSGS and pursues additional partnering opportunities in unlicensed territories.
The most recent analyst rating on (AU:DXB) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited (ASX: DXB) is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory diseases, particularly kidney disorders such as Focal Segmental Glomerulosclerosis (FSGS). Its lead asset, DMX-200, is a proprietary Phase 3 product candidate identified using the company’s own assay technology, and is being evaluated in a pivotal global Phase 3 trial (ACTION3) targeting patients with significant unmet medical needs in rare kidney disease.
Average Trading Volume: 1,161,102
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$336.2M
For detailed information about DXB stock, go to TipRanks’ Stock Analysis page.